Company: SHPH
Filing Date: 2025-03-19
Form Type: PRE 14A
Source: 0001493152-25-010886
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-19
Form: PRE 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a - 101)

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☒ | Preliminary                                                         
 Proxy Statement                                                     |
| ☐ | Confidential,                                                       
 for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) |
| ☐ | Definitive                                                          
 Proxy Statement                                                     |
| ☐ | Definitive                                                          
 Additional Materials                                                |
| ☐ | Soliciting                                                          
 Material Pursuant to §240.14a - 12                                  |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No                                                                                              
 fee required                                                                                    |
| ☐ | Fee                                                                                             
 paid previously with preliminary materials                                                      |
| ☐ | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11 |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLdIngS InC.</div>

2025 Annual Meeting of Stockholders

March [*], 2025

<div align='center'>Letter to Stockholders</div>

Dear Stockholders,

<div align='center'>[*]</div>

| /s/ Anatoly Dritschilo,                
 MD                                     |
| Anatoly Dritschilo, MD                 |
| Co-CEO                                 
 and Chairman of the Board of Directors |
| Shuttle Pharmaceuticals Holdings, Inc. |

Notice of Annual Meeting of Stockholders of Shuttle Pharmaceuticals Holdings, Inc.

| ITEMS                                                                                                                            
 OF BUSINESS                                                                                                                      
 Proposal                                                                                                                         
 No. 1: Elect five (5) directors named in the attached Proxy Statement to serve until the 2026 Annual Meeting of Stockholders.    
 Proposal                                                                                                                         
 No. 2: To ratify appointment of Forvis Mazars, LLP as the Company’s independent auditor for the fiscal year ending               
 December 31, 202